With the continuous efforts of pharmaceutical companies, domestic Class 1 antidepressant innovative drugs have been approved for marketing!

Depression is a common mental illness, and about 280 million people in the world suffer from depression
.
At present, the clinical treatment of depression by modern medical treatment mainly includes three types
: drug treatment, psychotherapy and physical therapy.
Among them, drug treatment is the main treatment for
depression.
Data show that in 2021, the sales of terminal antidepressants and chemical drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) have exceeded 8.
7 billion yuan.

However, it is worth noting that for a long time, almost all antidepressants in the domestic market have been developed by multinational pharmaceutical companies, and the products of local pharmaceutical companies are mainly
generic drugs.
It is gratifying that in recent years, with the rise of domestic pharmaceutical innovation, many pharmaceutical companies have begun to make efforts
in the field of antidepressants.
According to incomplete statistics, more than ten Class 1 innovative drugs in the field of depression research and development in China have been approved for clinical trial and above, involving many enterprises
such as Haosen Pharmaceutical, Huahai Pharmaceutical, Salubris Pharmaceutical, Luye Pharmaceutical, CSPC Pharmaceutical Group, Enhua Pharmaceutical and so on.
Among them, Luye Pharmaceutical's performance is very eye-catching
.
On November 3, Luye Pharmaceutical Group announced that its self-developed class 1 innovative drug Toludi venlafaxine hydrochloride sustained-release tablets (trade name: Ruoxinlin) was officially approved by the State Food and Drug Administration for the treatment of depression
。 It is understood that Ruoxinlin is the first class 1 innovative drug independently developed and has independent intellectual property rights for the treatment of depression in China, which was approved based on its six clinical studies in China, the results of which show that it can comprehensively and stably treat depression, significantly improve anxiety state, block/fatigue symptoms, anhedonia and cognitive ability, promote the recovery of social function, and has good safety and tolerability, does not cause drowsiness, does not affect sexual function, weight and lipid metabolism
。 At present, in addition to Luye Pharmaceutical, Huahai Pharmaceutical's hydroxypiperidone hydrochloride tablets and Jibel's JJH201501 tablets have completed phase II clinical trials
.
Phase II clinical trials such as amxetine hydrochloride enteric-coated tablets and GW117 capsules of Guangwei Pharmaceutical Group are also in progress
.
In fact, in addition to innovative drugs, in terms of antidepressant generic drugs, the layout of domestic pharmaceutical companies is also very active
.
It is reported that in July this year, Suoyuan Biologics announced that the international multi-center clinical phase II.
b trial (ENLIGHTEN study) of DB104 (liafensine) for the treatment of refractory depression (TRD) under the guidance of biomarkers was approved by the State Food and Drug Administration of China
.
It is reported that the drug is developed by AMRI/BMS, and Suoyuan Biotech obtained the global research and development, production and sales rights
of the drug in 2017 。 In June, Yongtai Technology issued an announcement that its subsidiary Zhejiang Yongtai Pharmaceutical was approved for imitating the enteric-coated capsules of the antidepressant duloxetine hydrochloride reported for production in Class 4, which was regarded as a review; In May, Jiangsu Haosen Pharmaceutical's vothioxetine hydrobromide tablets were approved for marketing, which was officially approved to enter China as early as 2017 for the treatment of adult depression.
.
.
In general, although for a long time, domestic antidepressants have basically occupied the market share by multinational pharmaceutical companies, and local pharmaceutical companies are mostly imitative, but with the continuous innovation of local pharmaceutical companies, the industry believes that the future market pattern may change
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.